Chik-Fong Wei
Cardiovascular Disease · Humble, TXNPI 1508968850
Payments from drug & device makers
Across 407 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Boston Scientific$922
- E.r. Squibb & Sons, L.L.C.$618
- Amarin Pharma, Inc.$605
- Abbott$587
- Bard Peripheral Vascular, Inc.$499
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,932100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 101 | $1,265 |
| Boston Scientific | 30 | $922 |
| E.r. Squibb & Sons, L.L.C. | 41 | $618 |
| Amarin Pharma, Inc. | 38 | $605 |
| Abbott | 10 | $587 |
| Bard Peripheral Vascular, Inc. | 15 | $499 |
| Boehringer Ingelheim | 18 | $451 |
| Pfizer | 20 | $411 |
| Merck | 18 | $307 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $299 |
| Johnson & Johnson | 14 | $297 |
| Sanofi-aventis U.S. LLC | 16 | $263 |
| Amgen | 13 | $230 |
| Novo Nordisk | 8 | $152 |
| Astellas Pharma US Inc | 7 | $152 |
| Esperion Therapeutics, Inc. | 10 | $124 |
| Tactile Systems Technology Inc | 9 | $117 |
| Impulse Dynamics (USA) Inc. | 3 | $109 |
| Cardiovascular Systems Inc. | 2 | $108 |
| AstraZeneca | 5 | $66 |
| Atricure, Inc. | 1 | $62 |
| Cvrx, Inc. | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Regeneron | 1 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Biotronik Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Heartflow, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Lemaitre Vascular, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ensite Cardiac Mapping System$431
- Watchman$238
- JARDIANCE$118
- VENOVO$100
How this compares
$7,953 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 13 | $106 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Humble
- Raymond LittleHumble$445K
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.